David Henry MD
Clinical Professor of Medicine, Pennsylvania Hospital, Philadelphia, PennsylvaniaIn addition to his clinical responsibilities, Dr. Henry is a member of the American Board of Internal Medicine’s Subspecialty SEP Board of Hematology and a principal investigator for the Eastern Cooperative Oncology Group, Accelerated Community Oncology Research Network, and International Oncology Network research groups. He is also principal investigator for several HIV oncology and cytokine studies with white blood cell and red blood cell growth factors. Dr. Henry’s main interests for publication and research are anemia and neutropenia in oncology. He is the Editor-in-Chief of MDEDGE.com/hematology-oncology and a reviewer for The New England Journal of Medicine, Journal of Clinical Oncology, Archives of Internal Medicine, and The Oncologist. He is also the author of a weekly podcast titled Blood and Cancer on iTunes.
Dr. Henry is a past winner of the annual Blockley-Osler Award for teaching at the University of Pennsylvania School of Medicine, and is the director of the University of Vienna medical student exchange program in Philadelphia. He also has appeared 3 times in Philadelphia magazine’s Top Doctors feature.
Positions:
Clinical Professor of Medicine, Pennsylvania Hospital, Philadelphia, PA
Member, Joan Karnell Cancer Center at Pennsylvania Hospital
Community oncologist
Degree:
University of Pennsylvania School of Medicine, MD
Postgraduate Training:
Resident, University of Pennsylvania School of Medicine
Fellow, University of Pennsylvania School of Medicine
Board Certification:
Medical oncology
Hematology
Clinical Interests:
Anemia, neutropenia, thrombocytopenia, and bone metastases
Recent Contributions to PracticeUpdate:
- ASCO 2022: Abstract Recommendations From Dr. David Henry for Oncology
- Quantitative Nodal Burden and Mortality Across Solid Cancers
- 2021 Top Story in Oncology: Surgically Preventing HPV-Related Anal Cancer in HIV-Infected Individuals
- VITTP and TTP From COVID Vaccinations and/or Infection
- PD-L1b Inhibitors for Nsq-NSCLC
- Poziotinib in Treatment-Naïve NSCLC With HER2 Exon 20 Mutations
- Cemiplimab With Platinum Doublet Chemo as First-Line for Advanced NSCLC
- Nivolumab Plus Ipilimumab vs Chemotherapy in Unresectable Mesothelioma
- Trastuzumab Deruxtecan for HER2-Mutated Metastatic NSCLC
- ESMO 2021: Recommendations From Dr. David Henry